

9.0 ANTINEOPLASTICS AND IMMUNOSUPPRESSANTS

9.1 ANTINEOPLASTICS

9.1.1 CELL-CYCLE-SPECIFIC AGENTS

S-Phase Specific Agents

9.1.1.1 Antimetabolites

CYTARABINE (1, 2)

Inj.: powder, 100 mg vial
(IM, SC, Intrathecal)
20 mg/mL, 5 mL ampul
(IM, SC, Intrathecal)
50 mg/mL, 10 mL vial (IV Infusion)

FLUOROURACIL (1, 2)

Inj.: 25 mg/mL, 10 mL vial
(IV, IV Infusion)
50 mg/mL, 5 mL, 10 mL, 20 mL
and 100 mL ampul/vial
(IV, IV Infusion)

MERCAPTOPYRINE (1)

Oral: 50 mg tablet

METHOTREXATE

Oral: 2.5 mg, 5 mg and 10 mg tablet
(as sodium salt) (B)

Inj.: 2.5 mg/mL, 2 mL and 8 mL vial
(IM, IV, Intrathecal)
(as sodium salt,
preservative-free)

5 mg/mL, 2 mL vial
(IM, IV, Intrathecal)
(as sodium salt,
preservative-free)

10 mg/mL, 1 mL and 5 mL vial
(IM) (as sodium salt)

25 mg/mL, 2 mL, 4 mL, 8 mL and
20 mL vial (IM, IV, Intrathecal)
(as sodium salt,
preservative-free)

100 mg/mL, 5 mL, 10 mL and
50 mL vial (IM, IV, Intrathecal)
(as sodium salt,
preservative-free)

CORE LIST	Complementary List	Route of Administration Pharmaceutical Forms and Strengths
	<i>gemcitabine</i> (1, 2)	Inj.: 200 mg vial (IV Infusion) (as hydrochloride) 1 g vial (IV Infusion) (as hydrochloride)
	<i>tegafur + uracil</i> (1, 2)	Oral: 100 mg + 224 mg capsule
9.1.1.2	Hydroxyurea (1, 2)	Oral: 500 mg capsule
9.1.1.3	Topoisomerase I Inhibitor	
	▼ <i>irinotecan</i> (1, 2)	Inj.: 40 mg/2 mL concentrate, vial (IV Infusion) (as hydrochloride) 100 mg/5 mL concentrate, vial (IV Infusion) (as hydrochloride)
9.1.1.4	Topoisomerase II Inhibitors	
	<i>DOXORUBICIN</i> (1, 2)	Inj.: powder, 10 mg, 20 mg and 50 mg vial (IV) (as hydrochloride) 2 mg/mL, 5 mL and 25 mL vial (IV) (as hydrochloride)
	<i>ETOPOSIDE</i> (1, 2)	Oral: 25 mg, 50 mg and 100 mg capsule Inj.: 20 mg/mL, 5 mL ampul/vial (IV) 20 mg/mL, 2.5 mL and 10 mL vial powder, 100 mg vial (IV)
	<i>daunorubicin</i> (1, 2)	Inj.: 2 mg/mL, 10 mL and 25 mL vial (IV)
	▼ <i>idarubicin</i> (1, 2)	Oral: 10 mg capsule Inj.: powder, 5 mg and 10 mg vial (IV) (as hydrochloride)
	<i>mitoxantrone</i> (1, 2)	Inj.: 2 mg/mL solution, 5 mL and 10 mL vial (IV) (as hydrochloride) 10 mg and 20 mg vial (IV) (as hydrochloride)
	G2-M Phase Specific Agents	
	<i>BLEOMYCIN</i> (1, 2)	Inj.: powder, 15 mg ampul (IM, IV, SC) (as sulfate)

Vinca Alkaloids

VINBLASTINE (1, 2)

Inj.: powder, 10 mg vial for reconstitution
(IV) (as sulfate)
1 mg/mL, 10 mL vial
(IV) (as sulfate),

VINCRISTINE (1, 2)

Inj.: 1 mg/mL, 1 mL, 2 mL and 5 mL vial
(IV) (as sulfate)
powder, 1 mg and 2 mg vial + diluent
(IV) (as sulfate)**Taxanes**

PACLITAXEL (1, 2)

Inj.: 6 mg/mL, 5 mL, 17 mL, 25 mL and
43.4 mL vial (IV, IV Infusion)
100 mg/15 mL, 15 mL multidose
vial (IV)
powder, 100 mg vial (IV)
powder, 260 mg vial (IV)

▼ docetaxel (1, 2)

Inj.: 20 mg/0.5 mL, 0.5 mL vial
(IV Infusion) (anhydrous)
40 mg/mL, 2 mL vial
(IV Infusion) (anhydrous)**9.1.2 NON-CELL-CYCLE-SPECIFIC AGENTS****9.1.2.1 Alkylating Agents**

CARMUSTINE (1, 2)

Inj.: powder, 100 mg vial + 3 mL vial
diluent (IV)

CHLORAMBUCIL (1, 2, B)

Oral: 2 mg tablet

CYCLOPHOSPHAMIDE (1, 2)

Oral: 50 mg tablet (as anhydrous) (B)
Inj.: powder, 100 mg, 200 mg, 500 mg
and 1 g vial (IV)

DACARBAZINE (1, 2)

Inj.: powder, 100 mg and 200 mg vial
(IV, IV Infusion)

IFOSFAMIDE (1, 2)

Inj.: powder, 1 g and 2 g vial
(IV Infusion)

LOMUSTINE (1, 2)

Oral: 300 mg combo-pack capsule

MELPHALAN (1, 2)

Oral: 2 mg tablet

CORE LIST	Complementary List	Route of Administration Pharmaceutical Forms and Strengths
★	<i>PROCARBAZINE</i> (1, 2)	Oral: 50 mg capsule (as hydrochloride)
	★ <i>busulfan</i> (1, 2)	Oral: 2 mg tablet
	★ <i>chlormethine</i> (<i>mechlorethamine</i> , <i>nitrogen mustard</i>) (1, 2)	Inj.: powder, 10 mg vial (IV, IV infusion, Intracavitary) (as hydrochloride)
	<i>epirubicin</i> (1, 2)	Inj.: powder, 10 mg and 50 mg vial (IV) (as hydrochloride)
	★ <i>estramustine</i> (1, 2)	Oral: 140 mg capsule Inj.: powder, 300 mg vial (IV) (as sodium phosphate)
9.1.2.2 Platinum Alkaloids		
	<i>CISPLATIN</i> (1, 2)	Inj.: powder, 10 mg, 25 mg, 50 mg and 100 mg vial (IV) 500 mcg/mL, 20 mL, 50 mL and 100 mL vial (IV) 1 mg/mL, 10 mL, 20 mL and 50 mL vial (IV)
	<i>carboplatin</i> (1, 2)	Inj.: powder, 150 mg and 450 mg vial (IV) 10 mg/mL, 5 mL, 15 mL, 45 mL and 50 mL vial (IV)
9.1.2.3 Antitumor Antibiotics		
	<i>BLEOMYCIN</i> (1, 2)	Inj.: powder, 15 mg ampul (IM, IV, SC) (as sulfate)
	<i>DACTINOMYCIN</i> (<i>actinomycin D</i>) (1, 2)	Inj.: powder, 500 mcg vial (IV)
	<i>mitomycin</i> (1, 2)	Oral: 1 mg tablet Inj.: powder, 2 mg and 10 mg vial (IV)
9.2 SEX HORMONES AND ANTAGONISTS IN MALIGNANT DISEASES		
	<i>FLUTAMIDE</i> (1, 2)	Oral: 250 mg tablet
	<i>MEGESTROL</i> (1, 2)	Oral: 40 mg and 160 mg tablet (as acetate)
	<i>TAMOXIFEN</i> (1, 2)	Oral: 10 mg, 20 mg, 30 mg and 40 mg tablet (as citrate)

★ *buserelin* (1, 2)Inj.: 1 mg/mL, 5.5 mL multidose
(SC) (as acetate)

Nasal Spray: 1 mg/mL, 10 mL vial

cyproterone (1, 2)

Oral: 50 mg tablet (as acetate)

Inj.: 100 mg/mL, 3 mL ampul, depot
(IM) (as acetate)*leuproreline* (1, 2)Inj.: 3.75 mg/ 2 mL vial with syringe
(IM, SC) (as acetate)powder (depot), 11.25 mg vial with
syringe (IM, SC) (as acetate)powder, 1.88 mg vial with
syringe (IM, SC) (as acetate)**9.3 IMMUNOTHERAPY****9.3.1 Immunomodulators***INTERFERON ALFA 2A*
(human) (1, 2)

Oral: 200 IU sublingual tablet

Inj.: 3 million IU, pre-filled syringe (IM, SC)

3 million IU, 4.5 million IU and
9 million IU per 1 mL vial
(SC, IM)4.5 million IU/0.5 mL pre-filled
syringe (SC)6 million IU/0.5 mL pre-filled
syringe (SC)9 million IU/0.5 mL pre-filled
syringe (IM, SC)

18 million IU/multidose vial (IM, SC)

INTERFERON ALFA 2B
(human) (1, 2)

Inj.: 3 million IU, 5 million IU and

10 million per mL vial + diluent
(IM, SC)*basiliximab* (1, 2)

Inj.: 20 mg vial (IV Infusion)

9.3.2 Immunosuppressants*AZATHIOPRINE* (1, 2)

Oral: 50 mg tablet

★ Inj.: freeze-dried powder, 50 mg vial
(IV, IV Infusion) (as sodium salt)*CICLOSPORIN* (1, 2)Oral: 25 mg, 50 mg and 100 mg capsule
100 mg/mL solution, 50 mLInj.: 50 mg/mL, 5 mL ampul
(concentrate) (IV Infusion)
(for organ transplant)

CORE LIST

Complementary List

Route of Administration

Pharmaceutical Forms and Strengths

mesna
(sodium -2-
mercapto
ethanesulphonate)
(1, 2)

Inj.: 100 mg/mL, 4 mL, 5 mL and
10 mL ampul (IV)

ondansetron
(for antineoplastic-
induced emesis)
(1, 2)

Oral: 8 mg tablet
(as hydrochloride dihydrate)
Inj.: 2 mg/mL, 2 mL and 4 mL ampul
(IM, IV)